Pay in 4 interest-free payments of $6.13 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Landmark Results The Phase 2 results, presented at the American Diabetes Association (ADA) Scientific Sessions in June 2023 and simultaneously published in the New England Journal of Medicine and The Lancet, were transformative: Weight loss : Up to 24.2% mean weight reduction at 48 weeks in the obesity trial (12 mg group), the highest ever reported for a pharmaceutical agent Glycemic control : Up to 2.02% HbA1c reduction in the diabetes trial, with most participants at higher doses achieving non-diabetic HbA1c levels Liver fat : Up to ~82% relative reduction in liver fat content Tolerability : GI adverse event profile consistent with the incretin class
LBA 13 Atkinson, R
McGavigan, A
US$ 26.07
US$ 28.88
US$ 23.93
